Contribute Try STAT+ Today

Behind almost every biotech IPO, every merger, and every buyout are a set of venture investors who stand to profit. In 2020, thanks to an extraordinary stock market and increased attention on the biopharma industry, those investors found themselves in a valuable spot.

Although relatively few pharmaceutical companies made big, flashy acquisition offers, investors were more than happy to welcome biotech companies onto the public markets. About 70 biotech companies made an initial public offering this year — including many that have yet to start a clinical trial — raising more than $14.5 billion.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • I am a STAT plus subscriber. I used my credentials to log in and I believe it is correct but I was not able to unlock the article.

Comments are closed.